Chymotrypsin lyophilisate for prig. solution for d / and places. approx. 10mg, # 10

• suppurative diseases of the respiratory system: bronchiectasis, pneumonia, lung abscess, atelectasis, exudative pleurisy, pleural empyema, bronchitis.

• burns;

• bedsores;

• purulent wounds;

• thrombophlebitis;

• periodontal disease (inflammatory-dystrophic forms);

• in ophthalmology: fresh extensive thrombosis of the central retinal vein, acute obstruction of the central retinal artery, opacity of the vitreous body of traumatic and inflammatory origin, cataract extraction;

• in otolaryngology: purulent sinusitis, subacute laryngotracheitis, after tracheostomy to facilitate the removal of thick viscous exudate, in acute, subacute, purulent, chronic otitis media and eustachitis with viscous exudate.

For intramuscular administration, immediately before use, 5 mg of the drug is dissolved in 1-2 ml of 0.9% sodium chloride solution for injection or 0.5-2% procaine solution. The course of treatment is 6-15 injections.

For diseases of the respiratory system, the drug is used intramuscularly in doses of 5-10 mg / day for 10-12 days, it is possible to combine it with the use of chymotrypsin aerosol in a 5% aqueous solution in an amount of 3-4 ml. After 7-10 days, the course of treatment can be repeated.

In the treatment of burns and bedsores, Chymotrypsin at a dose of 20 mg is dissolved in 20 ml of a 0.25% solution of procaine and a thin needle is injected under the scab with several injections.

Sterile wipes moistened with a solution of 25-50 mg of Chymotrypsin in 10-50 ml of a 0.25% solution of procaine are applied to purulent wound surfaces for 8 hours. For the treatment of purulent wounds, intramuscular injections of the drug are combined with local wound treatment with tampons moistened with a 5% aqueous solution of Chymotrypsin.

For thrombophlebitis, the drug is prescribed intramuscularly at 5-10 mg daily for 7-10 days.

For cataract extraction, Chymotrypsin at a dilution of 1: 5000 is injected into the posterior chamber of the eye, followed by rinsing the anterior chamber of the eye with 0.9% sodium chloride solution 4 minutes after drug administration.

In the treatment of thrombosis of the central retinal vein, acute obstruction of the central retinal artery, Chymotrypsin is administered subconjunctivally, 0.2 ml of a 5% solution prepared in 1% procaine solution, 1-2 times a week.

For sinusitis, the drug is injected into the appropriate cavity in an amount of 5-10 mg in 3-5 ml of 0.9% sodium chloride solution after puncture and rinsing of the cavity.

In case of otitis media, 0.5-1 ml of 0.1% Chymotrypsin solution in 0.9% sodium chloride solution is instilled into the ear.

When microoperations on the ear to soften the fibrinous formations in the middle ear during the operation, a 0.1% solution of Chymotrypsin is injected into the cavity. At the same time, chymotrypsin should be administered intramuscularly at 2.5-5 mg 1-2 times / day. The drug is diluted in 1-2 ml of a 0.25-0.5% solution of procaine or 0.9% sodium chloride solution for injection.

Lyophilisate for the preparation of a solution for injection, local and external use in the form of a tablet, lumps, powder, plates or shiny white scales.

1 fl.

chymotrypsin * 10 mg

* obtained from bovine pancreas.

• hypersensitivity;

• malignant neoplasms;

• pulmonary tuberculosis (open form);

• chronic heart failure II-III degree;

• dystrophy and cirrhosis of the liver;

• viral hepatitis;

• pancreatitis;

• hemorrhagic diathesis;

• pulmonary emphysema with respiratory failure.

It should not be injected into bleeding cavities, applied to the ulcerated surfaces of malignant tumors in order to avoid the spread of the malignant process.

With caution: pleural empyema of tuberculous etiology (resorption of exudate may in some cases contribute to the development of bronchopleural fistula).

pharmachologic effect

Hydrolyzes proteins and peptones, with the formation of relatively low molecular weight peptides, cleaves bonds formed by residues of aromatic amino acids (tyrosine, tryptophan, phenylalanine, methionine).

In medical practice, the use of Chymotrypsin is based on the specific feature of cleaving necrotic tissues and fibrinous formations, liquefying viscous secretions, exudates and blood clots, and, when administered intramuscularly, has an anti-inflammatory effect. In relation to healthy tissues, the enzyme is inactive and safe.

Side effect

Allergic reactions, increased body temperature to subfebrile, tachycardia.

After inhalation: irritation of the mucous membranes of the upper respiratory tract, hoarseness.

With subconjunctival administration, irritation and swelling of the conjunctiva are possible; in such cases, it is recommended to reduce the concentration of the solution used.

Local reactions after intramuscular injection: soreness and hyperemia at the injection site may occur.

Application during pregnancy and lactation

There is no data on the use of the drug during pregnancy and lactation.

special instructions

Influence on the ability to drive vehicles and use mechanisms

There were no negative effects on the ability to drive vehicles and mechanisms.

Overdose

There is no evidence of an overdose.

Drug interactions

Not described.